Heart Failure Patients Registry

Primary outcomes

1. Mean age

   Time frame: Baseline

   At baseline of this study

2. Proportion of men and women

   Time frame: Baseline

   At baseline of this study

3. Proportion of patients with negative lifestyle factors

   Time frame: Baseline

   At baseline of this study

4. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different etiology of CHF

   Time frame: Baseline

   At baseline of this study

5. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with a history of HF comorbidities and conditions of special interest

   Time frame: Baseline

   At baseline of this study

6. Mean duration of comorbidities listed in previous paragraph (p. 5) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

   Time frame: Baseline

   At baseline of this study

7. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different chronic comorbidities

   Time frame: Baseline

   At baseline of this study

8. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with history of COVID-19

   Time frame: Baseline

   At baseline of this study

9. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with vaccination

   Time frame: Baseline

   At baseline of this study

10. Proportion of patients with different types of HF based on LVEF

    Time frame: Baseline

    At baseline of this study

11. Proportion of patients with T2DM comorbid with different types of HF based on LVEF

    Time frame: Baseline

    At baseline of this study

12. Mean HbA1c (for patients with T2DM) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF);

    Time frame: Baseline

    At baseline of this study

13. Proportions of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different levels of HbA1c (for patients with T2DM)

    Time frame: Baseline

    At baseline of this study

14. Mean BMI (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

15. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different BMI levels

    Time frame: Baseline

    The BMI will be calculated using a formula based on the patient's anthropometric data collected at visit q (height measured in meters and body weight measured in kilograms). BMI (kg / m2) is calculated using the formula: BMI = weight (kg) / (height2 (m2))

16. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of CHF according to NYHA classification based on patient symptoms of HF

    Time frame: Baseline

    At baseline of this study

17. Mean NT-proBNP level (or BNP)

    Time frame: Baseline

    NT-proBNP is measured in pg / mL. At baseline of this study

18. Mean heart rate (HR) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF);

    Time frame: Baseline

    At baseline of this study

19. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of HF according to SHOKS level

    Time frame: Baseline

    • Functional Class I - ≤3 points;
    • Functional Class II - from 4 to 6 points;
    • Functional Class III - from 7 to 9 points;
    • Functional Class IV - more than 9 points;

    At baseline of this study.

20. Mean SBP (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    SBP - Systolic blood pressure. At baseline of this study.

21. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with SBP

    Time frame: Baseline

    • <90 mm Hg;
    • 90-99 mm Hg;
    • 100-109 mm Hg;
    • 110-119 mm Hg;
    • 120-139 mm Hg;
    • 140-159 mm Hg;
    • ≥160 mm Hg;

    At baseline of this study

22. Mean Diastolic blood pressure (DBP) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

23. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with DBP

    Time frame: Baseline

    • <90 mm Hg;
    • ≥90 mm Hg;

    At baseline of this study

24. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with concomitant CKD of different stages

    Time frame: Baseline

    eGFR = 141 x min(SCr/κ, 1)^α x max(SCr/κ, 1)^-1.209 x 0.993^Age x 1.018 [if female] x 1.159 [if Black], where eGFR (estimated glomerular filtration rate) = mL/min/1.73 m^2, SCr (standardized serum creatinine) = mg/dL, κ = 0.7 (females) or 0.9 (males), α = -0.329 (females) or -0.411 (males), min = indicates the minimum of SCr/κ or 1, max = indicates the maximum of SCr/κ or 1, age = years.

    At baseline of this study

25. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CKD and different levels of albumin-to-creatinine ratio in a spot urine sample

    Time frame: Baseline

    • <30 mg/g;
    • 30-300 mg/g;
    • >300 mg/g;

    At baseline of this study

26. Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hyperkalemia (K+ level >5,5 mmol/L)

    Time frame: Baseline

    At baseline of this study

27. Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hypokalemia (K+ level <3,5 mmol/L)

    Time frame: Baseline

    At baseline of this study

28. Mean LVEF (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

29. Mean K+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

30. Mean Na+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

31. Mean hemoglobin level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

    Time frame: Baseline

    At baseline of this study

32. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different rhythm

    Time frame: Baseline

    • Sinus rhythm;
    • AF / AFl;
    • Pacemaker rhythm;

    At baseline of this study

33. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different QRS duration

    Time frame: Baseline

    • <130 ms;
    • 130-150 ms;
    • >150 ms;

    At baseline of this study

34. Proportion of patients receiving different classes of drugs for treatment of HF

    Time frame: Baseline

    • ACE inhibitors (duration, dosage, proportion of patients receiving: <50% of target dose, 50-100% of target dose, ≥100% of target dose);
    • B-blockers (duration, dosage, proportion of patients receiving: <50% of target dose, 50-100% of target dose, ≥100% of target dose);
    • ARBs (duration, dosage, proportion of patients receiving: <50% of target dose, 50 100% of target dose, ≥100% of target dose);
    • MRAs (duration, dosage, proportion of patients receiving: <50% of target dose, 50 100% of target dose, ≥100% of target dose);
    • ARNI (duration, dosage, proportion of patients receiving: <50% of target dose, 50 100% of target dose, ≥100% of target dose);

    At baseline of this study

35. Proportion of patients with HFrEF with implantable devices

    Time frame: Baseline

    • Implantable cardioverter-defibrillator (ICD) (recommended; implanted);
    • Cardiac resynchronisation therapy (CRT) (recommended; implanted);
    • CRT with defibrillation (CRT-D) (recommended; implanted);
    • Left ventricular assist device (LVAD);

    At baseline of this study

36. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with cardiac surgery and endovascular procedures

    Time frame: Baseline

    • Revascularisation with PCI;
    • Revascularisation with CABG;
    • Valvular surgery;
    • Heart transplantation;

    At baseline of this study

37. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving dual disease-modifying therapy

    Time frame: Baseline

    At baseline of this study

38. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving triple disease-modifying therapy

    Time frame: Baseline

    At baseline of this study

39. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving quadruple disease-modifying therapy

    Time frame: Baseline

    At baseline of this study

40. Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CHF receiving different classes of glucose lowering drugs and their combinations for T2DM treatment

    Time frame: Baseline

    • Modification of diet and lifestyle only;
    • Metformin;
    • Sulfonylureas;
    • Inhibitors of dipeptidyl peptidase-4 (iDPP4);
    • iSGLT2;
    • Glucagon-like peptide-1 receptor agonists (GLP1 RA);
    • Acarbose;
    • Insulins.

    At baseline of this study